Relationship Between Topiramate Use and Ocular Angle Status

Chinese University of Hong Kong15 enrolled

Overview

We test the hypothesis whether topiramate narrows the angles which may render Asians more likely to suffer from acute angle closure glaucoma.

Topiramate is approved for the treatment of epilepsy and prophylaxis of migraine attacks. There were case reports of acute angle closure glaucoma (AACG) associated with its use. AACG is particularly common in Asians because of a higher prevalence of narrow angle., we test the hypothesis whether topiramate narrows the angles which may render them more likely to suffer from AACG.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Glaucoma, Angle-Closure

Interventions

TopiramateDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participants aged 18-75 with an indication for starting topiramate. Exclusion Criteria: * Patients with known allergy or intolerance to topiramate. * Recent exposure to topiramate (\<3 months). * Moderate to severe renal failure. * Known history of renal calculi or hepatic failure * Inability to give informed consent. * Pregnant women or women of child-bearing age who do not practise an acceptable means of contraception. * Patients known to have angle-closure glaucoma.

Locations (2)

Hong Kong Eye Hospital

Kowloon, Hong Kong

Prince of Wales Hospital

Shatin, Hong Kong

Outcomes

Primary Outcomes

Change(s) in ophthalmic parameters measured at baseline and after 4 weeks of treatment, including:

Time frame: 4 weeks

best-corrected visual acuity, refraction, Goldmann applanation tonometry, Gonioscopy, dilated fundus examination,

Time frame: 4 weeks

and ultrasound biomicroscopy of angle and anterior segment.

Time frame: 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.